Открыть главное меню
Главная
Случайная
Войти
Настройки
О hpluswiki
Отказ от ответственности
hpluswiki
Найти
Редактирование:
OMG
Внимание:
Вы не вошли в систему. Ваш IP-адрес будет общедоступен, если вы запишете какие-либо изменения. Если вы
войдёте
или
создадите учётную запись
, её имя будет использоваться вместо IP-адреса, наряду с другими преимуществами.
Анти-спам проверка.
Не
заполняйте это!
Oligodendrocyte-myelin glycoprotein precursor [OMGP] ==Publications== {{medline-entry |title=Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/18602121 |abstract=The aims of this study were to obtain data on the frequency with which Korean patients with autoimmune myasthenia gravis (MG) present solely with ocular disturbances and progress to develop generalized disease and to identify the prognostic factors associated with secondary generalization. We conducted a retrospective multicenter survey in which a total of 376 adult patients who were newly diagnosed with MG from 2000 through 2005 were reviewed for analysis. Patients with ocular MG at the time of symptom presentation (n=202, 53.7%) were divided into two subgroups according to their prognosis: the patients whose disease remained ocular throughout the follow-ups were placed in the [[OMG]]-R group, and the patients who progressed to develop generalized disease were placed in the [[OMG]]-G group. Clinical characteristics and laboratory findings were compared between the two subgroups. Secondary generalization developed in 47 (23.3%) of the 202 study subjects, mostly within the first 6 months after symptom presentation, while the disease remained ocular throughout the follow-up duration (median 11.8 months) in the remaining 155 patients (76.7%). AChR antibody, abnormal repetitive nerve stimulation tests (RNST) and thymoma were more frequently observed in the patients in the [[OMG]]-G group than in those in the [[OMG]]-R group (p<0.01 in all). In seropositive cases, the titers of AChR antibody were also significantly higher in the [[OMG]]-G group than in the [[OMG]]-R group (median, 3.8 nM vs. 6.4 nM; p<0.05). Cox proportional hazards regression analyses showed that early oral prednisolone treatment significantly reduced the risk of secondary generalization (HR, 0.24; 95% CI, 0.11-0.56), whereas abnormal AChR antibody (HR, 5.34; 95% CI, 1.60-17.8) and thymoma (HR, 2.32; 95% CI, 1.21-4.45) were predictive of the development of secondary generalization. Our findings suggest that several factors, including the AChR antibody, thymoma, early corticosteroid treatment, and possibly latent neuromuscular abnormality revealed by RNST, may have an impact on the risk of developing generalized disease in Korean patients presenting with ocular myasthenia. |mesh-terms=* Adult * Aged * Aged, 80 and over * Aging * Analysis of Variance * Female * Humans * Korea * Male * Middle Aged * Myasthenia Gravis * Prognosis * Receptors, Cholinergic * Retrospective Studies * Statistics, Nonparametric |full-text-url=https://sci-hub.do/10.1016/j.jns.2008.05.023 }} {{medline-entry |title=Research note: age-dependent changes in 3-oxy-methyl-D-glucose and leucine intestinal absorption in chickens. |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/1409240 |abstract=Intestinal absorption of 3-oxy-methyl-D-glucose (3-[[OMG]]) and leucine were studied in intestinal slices from fasted 1-, 2-, and 3-wk-old chickens. The intestinal segments studied were the duodenum, jejunum, ileum, and cecum, with the latter divided into proximal and medial regions. There was a decrease in the intestinal absorption of 3-[[OMG]] and leucine in the duodenal, jejunal, and proximal cecal segments with increasing age of the chicken. The medial cecum did not show age-dependent differences in the uptake of substrates. In the ileum, there was a decrease in intestinal absorption of 3-[[OMG]] and leucine between Weeks 1 and 2, but thereafter the uptake was similar to that of the 2nd wk. |mesh-terms=* 3-O-Methylglucose * Aging * Animals * Chickens * Intestinal Absorption * Leucine * Male * Methylglucosides |full-text-url=https://sci-hub.do/10.3382/ps.0711556 }}
Описание изменений:
Пожалуйста, учтите, что любой ваш вклад в проект «hpluswiki» может быть отредактирован или удалён другими участниками. Если вы не хотите, чтобы кто-либо изменял ваши тексты, не помещайте их сюда.
Вы также подтверждаете, что являетесь автором вносимых дополнений, или скопировали их из источника, допускающего свободное распространение и изменение своего содержимого (см.
Hpluswiki:Авторские права
).
НЕ РАЗМЕЩАЙТЕ БЕЗ РАЗРЕШЕНИЯ ОХРАНЯЕМЫЕ АВТОРСКИМ ПРАВОМ МАТЕРИАЛЫ!
Отменить
Справка по редактированию
(в новом окне)
Шаблон, используемый на этой странице:
Шаблон:Medline-entry
(
править
)